PLPL the medical marijuana miracle?

Recommended Stock Newsletters
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

PennyStockGeneral Newsletter

Undiscovered "Pot Play":

Plandai Biotechnology, Inc (PLPL)    

Traders ,   I`m excited about the prospects of PLPL doing well today.   PLPL is one of the few marijuana related companies that has not yet run big.   While most other pot plays have shot up 100%, 500%, even 1,000% over the past few days/weeks, PLPL has only just started getting some interest yesterday.   And best of all, the price of PLPL is not even close to where it was trading just a few weeks ago.   In December, PLPL was trading at around $0.50. Today it is priced at only $0.295.   And while many other marijuana stocks have market caps of $50-100 million, PLPL has a market cap just over $30m.   We think PLPL is one of the few marijuana plays that could see big gains in the days ahead.   Check out what we had to say about PLPL last night in more detail below…   All the best today.   >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>   Traders ,


Our alert today on EMBR yesterday did great, giving us multiple chances for solid gains – over 100% in fact if you are a keen day trader/dip buyer… And today it continued its run gaining another 20% to hit new highs of $0.205.   Tomorrow`s alert is no stranger to us. In fact every time we have alerted it, we have seen nice short term gains – in fact it gained 45% in 2 days on one of our alerts.   But this time, we are more bullish than ever on Plandai Biotechnology, Inc (PLPL).   Let me get straight to the point. The price action I witnessed in PLPL today was awesome.    And the big reason is (well there are a few) marijuana .   Investors are waking up to the massive potential of PLPL in the medical marijuana industry.   >> Just read this recent press release from PLPL about the direction they are headed in this field <<   Unless you have been living under a rock lately , you would have noticed any company (even remotely) related to the marijuana industry have seen ridiculously big gains lately.   PHOT – up 212% in one month TRTC – up 150% in less than two weeks GRNH – up over 900% in 4 trading days   … And the list keeps going.

  And PLPL is perfectly positioned to succeed in the medical marijuana industry (read more about PLPL in detail below).

  Investors are finally waking up to PLPL`s excellent prospects in the marijuana industry and the company`s significant land holdings and infrastructure, its vast experience with R&D in plant extracts, and proprietary technology.    PLPL could become a giant in the marijuana industry in the future .   We have also seen PLPL pull back significantly from its highs a few months ago of $0.82. Closing at just $0.295 today, it could be an extraordinary dip buying opportunity .   We liked PLPL as a "go to" low risk/high reward trader before, now we love it so much more.

  Look at the chart further on down below.   PLPL was way oversold when it broke support Mid-December. Once stop-losses got taken out, it was in free fall, until smart money came in buying up cheap shares.   Second, technically PLPL needs to "fill the gap" .   This means that it is very likely to re-test former support of $0.40. This also happens to be the 50 day moving average, so it makes perfect sense that traders would buy PLPL up to $0.40ish.   At yesterdays closing price of $0.295, this would be a 36% gain.   But with all the buzz around marijuana companies right now, we would expect much bigger gains in the days and weeks ahead .

  In the chart you will see a strong bounce taking place, an oversold RSI, MACD ticking up and a resistance magnet that intersects with the 50 day moving average – all very bullish signals .


  Here`s an in-depth look into PLPL


Plandai Biotechnology (PLPL)  intends to transform the world of nutraceuticals and is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 8500 acres, in the province of Mpumalanga, South Africa. This Seattle based biotechnology firm uses a proprietary process that is dramatically improving the bioavailability of their compounds through molecular changes to the live botanicals themselves.   PLPL controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare(TM) extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company`s products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.   ==> The Future with PLPL Starts Here <==

  What is Phytofare(TM)

The company`s patented hydrodynamic sheering process through which live plant-materials are converted at the molecular level during extraction into a nano-particle structure that mimics that found in human tissues.  Where most botanical products have less than 10% absorption, according to the company and documented research, Phytofare(TM) is clinically proven to have far superior absorption. 

Higher bioavailability translates into the ability for users to receive a clinical dose with lower quantities.  By definition, when a medication is administered intravenously, its bioavailability is 100%.  When a medication is administered in any other way, orally for instance, its bioavailability generally decreases due to incomplete absorption and may vary from patient to patient.  Bioavailability can be defined as a measurement of the amount of any compound to be absorbed into the bloodstream.

In short, PlandaĆ­ takes the good, removes the bad and amplifies the benefits of nutrients to manufacture better food and drinks through better technology.  PLPL has collaborated with some of the biggest and brightest minds in the food and beverage industry. 

=>> In Depth Fact Check on the amazing Plandai Biotechnology <==

  According to the Company, PLPL will look to introduce 3 separately branded extracts that will offer customers the high bioavailability that its patented technology can provide.

Green Tea Catechin Extract

Citrus Limonoid Glycoside Complex

Carotenoid Botanical Extract Addressing a number of the most talked about areas in the industry, these extracts will look to offer preventative and inhibitive options for:  cancer prevention, anti-viral protection, anti-inflammation, antioxidants, weight loss, high blood pressure, and sports injury recovery.   And the positive news keeps coming for PLPL. Take a look below at all the headlines hitting the wires recently, especially with regards to its medical marijuana operations…


Plandai Biotechnology`s CEO Discusses Direction of Medical Marijuana Subsidiary Plandai Biotechnology, Inc. Announces Intellectual Property Filings Plandai Biotechnology, Inc. to Focus Marijuana Research on Neuron Disorders Including Alzheimer`s, Parkinson`s, and Multiple Sclerosis Plandai`s Medical Marijuana Research Could Benefit From FDA Approval of Clinical Trials Plandai to Provide New Formula in Diet Industry Profit Quest New Report Shows Plandai Biotechnology`s Diabetes Research More Important Than Ever Plandai Biotechnology`s Move Into Medical Marijuana Research Gets Validation With New Study Plandai Enters Medical Marijuana Market Plandai Biotechnology Enters Medical Marijuana Arena With Industry-Changing Technology Plandai Biotechnology, Inc. to Enter Medical Marijuana Field With Phyto Cannabinoid Extract Plandai Preparing for Strong 2014  PLPL is one of the few marijuana companies that is yet to explode. While most other "pot stocks" have already gained big, the best risk/return is by far and away in a company like PLPL.   I urge you to keep PLPL on the top of your watch list tomorrow and throughout the next couple of weeks.   I would just hate for you to miss the boat on this one.

  Talk soon,

The Team  

Click Below to Join Our Social Media Networks


Normal 0

false false false


—————————————————————————————————- DISCLAIMER ——————————————————————————————————

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

Full disclaimer can be read here employees are not registered as an Investment Adviser in any jurisdiction whatsoever.

The disclaimer is to be read and fully understood before using our site, or joining our email list.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.  Instead Pennystockgeneral .com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. does not offer such advice or analysis, and Pennystockgeneral .com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor`s investment may be lost or impaired due to the speculative nature of the companies profiled.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, Pennystockgeneral .com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Pennystockgeneral .com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Pennystockgeneral .com is not responsible for any claims made by the companies advertised herein.

Pennystockgeneral .com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in Pennystockgeneral .com statements and opinions and such statements and opinions cannot be considered independent. Pennystockgeneral .com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, Pennystockgeneral .com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. Pennystockgeneral .com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. Pennystockgeneral .com has been compensated two thousand dollars from a non-affiliated third party for this profile of PLPL.

Pennystockgeneral .com may on occasion accept compensation in restricted or free-trading shares for it`s marketing services of the company being profiled, and the third party that might have compensated Pennystockgeneral .com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.  If Pennystockgeneral .com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services .

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:"Times New Roman"; mso-fareast-theme-font:minor-fareast; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

244 5th Ave, New York, NY 10001

This entry was posted in Stock Newsletters and tagged , , , , . Bookmark the permalink.

Comments are closed.